3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
18
Terminated
3
Active not recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
13
Neoplasms
7
Brain Neoplasms
6
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Adenocarcinoma of Lung
2
Tongue Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Diseases
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Precancerous Conditions
1
Optic Nerve Glioma
1
Non-squamous Non-small Cell Lung Cancer
1
Metastatic Pancreatic Adenocarcinoma
1
Medulloblastoma
1
Lung Diseases
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Interventions
Cisplatin
22
Radiotherapy
15
Cetuximab
12
Docetaxel
11
Carboplatin
10
pembrolizumab
8
toripalimab
6
camrelizumab
6
Paclitaxel
5
Nivolumab
5
Neoadjuvant Therapy
5
Fluorouracil
5
Drug Therapy
5
Chemoradiotherapy
5
nimotuzumab
4
durvalumab
4
sintilimab
3
cemiplimab
3
apatinib
3
advexin
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Immunohistochemistry
3
Celecoxib
3
Blood Specimen Collection
3
nedaplatin
2
Therapeutics
2
Tegafur
2
Radiotherapy, Intensity-Modulated
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Squamous Cell Carcinoma of Head and Neck
×
Erlotinib Hydrochloride
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled